Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÇiçek, Gökhan
dc.contributor.authorUyarel, Hüseyin
dc.contributor.authorErgelen, Mehmet
dc.contributor.authorAyhan, Erkan
dc.contributor.authorAbanonu, Gül Babacan
dc.contributor.authorEren, Mehmet
dc.contributor.authorGibson, Charles Michael
dc.date.accessioned2019-10-16T11:44:14Z
dc.date.available2019-10-16T11:44:14Z
dc.date.issued2011en_US
dc.identifier.issn0954-6928
dc.identifier.issneISSN: 1473-5830
dc.identifier.urihttps://doi.org/ 10.1097/MCA.0b013e328342c760
dc.identifier.urihttps://hdl.handle.net/20.500.12462/7191
dc.descriptionUyarel, Hüseyin (Balikesir Author)en_US
dc.description.abstractObjectives We sought to determine the effect of hemoglobin A1c (HbA1c) on the outcomes of primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Background Diabetes mellitus (DM) can be diagnosed from a level of at least 6.5% on two separate occasions according to the American Diabetes Association (ADA) definition, which was updated in 2010. No data are available for the value of HbA1c in patients with STEMI treated with primary PCI. Methods A total of 374 consecutive patients with STEMI (mean age: 55.9 +/- 12.6 years, 318 men), undergoing primary PCI between December 2009 and June 2010, were prospectively enrolled in this study. Blood samples for HbA1c were obtained on the first 24 h after admission. In-hospital follow-up was performed. By using new ADA criteria, patients were classified into three groups: group I (HbA1c <= 5.6%, n=112); group II (HbA1c: 5.7-6.4%, n= 180); and group III (HbA1c >= 6.5%, n= 82). Results In-hospital mortality was higher in group III (11%) compared with group II (2.8%) and group I (0.9%; P=0.001). Major adverse cardiac events in the hospital were also higher in group III (12.2%) compared with other groups (group II, 5.6% vs. group I, 0.9%, P=0.003). After adjusting the baseline characteristics, HbA1c remained a strong independent predictor of the in-hospital mortality (odds ratio: 1.412; 95% confidence interval: 1.031-1.935, P=0.03). Hospital stay was also longer in group III than others (P=0.007). A total of 196 (63.6%) patients without a history of diabetes mellitus had elevated HbA1c of more than or equal to 5.7%, with 31 (10.1%) of them having HbA1c of more than or equal to 6.5%. Conclusion HbA1c is an independent predictor of the in-hospital mortality in STEMI treated with primary PCI. Apart from prognostic value, high HbA1c could be used for diabetes mellitus diagnosis, which is supported by ADA definitions. Coron Artery Dis 22:131-137en_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.isversionof10.1097/MCA.0b013e328342c760en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute Myocardial İnfarctionen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectHemoglobin A1cen_US
dc.subjectPrimary Angioplastyen_US
dc.titleHemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarctionen_US
dc.typearticleen_US
dc.relation.journalCoronary Artery Diseaseen_US
dc.contributor.departmentTıp Fakültesien_US
dc.identifier.volume22en_US
dc.identifier.issue3en_US
dc.identifier.startpage131en_US
dc.identifier.endpage137en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster